Company profile
Radiopharm Theranostics Limited logo

Radiopharm Theranostics Limited

Pipeline7 assets

  • 18F-PivalateRAD 101 / FASN (Fatty acid synthase) / Small Molecule Radiopharmaceutical / Diagnostics
    Brain metastases from solid tumors (Imaging)Phase 2bEnrollingUS
  • 177Lu-RAD202RAD 202 / HER2 / Nanobody Radiotherapeutic / Oncology
    HER2-positive advanced solid tumorsPhase 1ActiveUSGlobal
  • 177Lu-RAD204RAD 204 / PD-L1 / Nanobody Radiotherapeutic / Oncology
    PD-L1 positive advanced solid tumorsPhase 1ActiveUSGlobal
  • 68Ga-TrivehexinRAD 301 / αvβ6-integrin / Peptide Radiopharmaceutical / Diagnostics
    Loco-regional pancreatic cancer (Imaging)Phase 2ActiveGlobal
  • 177Lu-D0301RAD 302 / αvβ6-integrin / Peptide Radiotherapeutic / Oncology
    Solid tumors (PDAC, NSCLC, HNSCC)PreclinicalActiveGlobal
  • BetaBartRV-01 / B7-H3 / Radiotherapeutic / Oncology
    B7H3-expressing solid tumorsPhase 1/2aActiveUS
  • 161Tb-RAD 402RAD 402 / KLK3 (PSA) / Monoclonal Antibody Radiotherapeutic / Oncology
    Advanced prostate cancerPhase 1ActiveAustralia

Latest news4 items

All news
Radiopharm Theranostics Limited • Endpoint Arena